drugset / Trial / NCT02595060

Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) Inhalation to Improve Host Defense and Pulmonary Barrier Restoration

NCT02595060

Phase 2 Completed 45 enrolled University of Giessen
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This trial evaluates efficacy and safety of inhaled molgramostim (rhGM-CSF) in 45 patients with pneumonia associated acute respiratory distress syndrome (ARDS). A third of the patients will receive 150 mcg inhaled molgramostim, another third 450 mcg and the remaining third will receive inhaled placebo for 3 days. The patients will be followed for 28 days.

Timeline

Start
2016-06-01
Primary completion
2021-09-22
Completion
2022-07-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Molgramostim Protein / enzyme biologic 150 ug Inhaled
Subject Molgramostim Protein / enzyme biologic 450 ug Inhaled